GlassScriptPhysician profile
Justin Wu Marson
NPI 1831650548
$18,042.90
in general payments reported to CMS, 2019-2025
25 companies · $4,201 in 2025
The $4,201 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2022: $2,504 · 2023: $5,500 · 2024: $5,702 · 2025: $4,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $69.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,333.14 |
| Education | $69.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $4,048.72 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Dermavant Sciences, INC. | $2,386.42 | 2022-2024 | Vtama |
| Incyte Corporation | $1,529.57 | 2022-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $1,320.57 | 2022-2025 | Sotyktu |
| Ucb, INC. | $966.38 | 2022-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $945.31 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $900.76 | 2022-2025 | |
| Genzyme Corporation | $890.46 | 2023-2025 | |
| Pfizer INC. | $670.86 | 2021-2024 | |
| Abbvie INC. | $618.44 | 2023-2025 | |
| Leo Pharma INC. | $552.32 | 2023-2025 | Adbry, Anzupgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $466.66 | 2022-2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $445.23 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $429.10 | 2021-2025 | Nemluvio |
| Lilly USA, LLC | $312.09 | 2024-2025 | Ebglyss, Taltz, Zepbound |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $293.17 | 2025 | |
| Verrica Pharmaceuticals INC. | $271.55 | 2023-2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $241.71 | 2021-2024 | Cabtreo |
| Helsinn Therapeutics (U.S.), INC. | $186.43 | 2022-2024 | Valchlor |
| Chiesi USA, INC. | $164.50 | 2024-2025 | Filsuvez |
| Organon LLC | $150.00 | 2025 | Vtama |
| Janssen Biotech, INC. | $107.15 | 2024-2025 | Tremfya |
| Amgen INC. | $66.74 | 2023-2025 | Amjevita |
| Regeneron Healthcare Solutions, INC. | $58.67 | 2022-2024 | Dupixent |
| Almirall LLC | $20.09 | 2025 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Marson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.